Lung transplantation for pulmonary fibrosis in dyskeratosis congenita: Case Report and systematic literature review

BMC Blood Disorders

Volumn 11, Issue , 2011, Pages

  Giri, Neelam ^a   Lee, Rees ^b   Faro, Albert ^c   Huddleston, Charles B ^c   White, Frances V ^c   Alter, Blanche P ^a   Savage, Sharon A ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b NAVAL MEDICAL CENTER PORTSMOUTH   (United States)

^c WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLCYSTEINE; AZATHIOPRINE; CARBON MONOXIDE; CYCLOPHOSPHAMIDE; CYCLOSPORIN; METHOTREXATE; METHYLPREDNISOLONE; PREDNISONE; STEROID; TACROLIMUS; THYMOCYTE ANTIBODY;

ADOLESCENT; APLASTIC ANEMIA; ARTICLE; ARTIFICIAL VENTILATION; ASIAN; BONE MARROW DEPRESSION; CASE REPORT; CELL PROLIFERATION; COUGHING; DISEASE SEVERITY; DRUG MEGADOSE; DYSKERATOSIS CONGENITA; DYSPNEA; EXPLANT; FAMILY HISTORY; FIBROSING ALVEOLITIS; FORCED EXPIRATORY FLOW; FORCED EXPIRATORY VOLUME; FORCED VITAL CAPACITY; GENE MUTATION; GRAFT VERSUS HOST REACTION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HLA MATCHING; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; LACRIMAL DUCT OCCLUSION; LEUKOCYTE COUNT; LEUKOPLAKIA; LOW DRUG DOSE; LUNG ALVEOLUS CELL; LUNG BIOPSY; LUNG DIFFUSION CAPACITY; LUNG FIBROBLAST; LUNG FUNCTION TEST; LUNG TRANSPLANTATION; LUNG VENTILATION PERFUSION RATIO; MAINTENANCE THERAPY; MALE; NAIL DYSTROPHY; NEUTROPENIA; POSITIVE END EXPIRATORY PRESSURE; SKIN FIBROBLAST; SKIN PIGMENTATION; SPIROMETRY; THORAX RADIOGRAPHY; THROMBOCYTOPENIA; TOTAL LUNG CAPACITY; TRICHIASIS; URETHRA STENOSIS;

EID: 79958769846     PISSN: None     EISSN: 14712326     Source Type: Journal    
DOI: 10.1186/1471-2326-11-3     Document Type: Article

References (55)

1. Savage SA, Alter BP. Dyskeratosis congenita. Hematol Oncol Clin North Am 2009, 23:215-231. 10.1016/j.hoc.2009.01.003, 2702847, 19327580.
2. Alter BP, Giri N, Savage SA, Rosenberg PS. Cancer in dyskeratosis congenita. Blood 2009, 113:6549-6557. 10.1182/blood-2008-12-192880, 2710915, 19282459.
3. Alter BP, Baerlocher GM, Savage SA, Chanock SJ, Weksler BB, Willner JP, Peters JA, Giri N, Lansdorp PM. Very short telomere length by flow fluorescence in situ hybridization identifies patients with dyskeratosis congenita. Blood 2007, 110:1439-1447. 10.1182/blood-2007-02-075598, 1975834, 17468339.
4. Heiss NS, Knight SW, Vulliamy TJ, Klauck SM, Wiemann S, Mason PJ, Poustka A, Dokal I. X-linked dyskeratosis congenita is caused by mutations in a highly conserved gene with putative nucleolar functions. Nat Genet 1998, 19:32-38. 10.1038/ng0598-32, 9590285.
5. Vulliamy T, Marrone A, Goldman F, Dearlove A, Bessler M, Mason PJ, Dokal I. The RNA component of telomerase is mutated in autosomal dominant dyskeratosis congenita. Nature 2001, 413:432-435. 10.1038/35096585, 11574891.
6. Vulliamy TJ, Walne A, Baskaradas A, Mason PJ, Marrone A, Dokal I. Mutations in the reverse transcriptase component of telomerase (TERT) in patients with bone marrow failure. Blood Cells Mol Dis 2005, 34:257-263. 10.1016/j.bcmd.2004.12.008, 15885610.
7. Walne AJ, Vulliamy T, Marrone A, Beswick R, Kirwan M, Masunari Y, Al-Qurashi FH, Aljurf M, Dokal I. Genetic heterogeneity in autosomal recessive dyskeratosis congenita with one subtype due to mutations in the telomerase-associated protein NOP10. Hum Mol Genet 2007, 16:1619-1629. 10.1093/hmg/ddm111, 2882227, 17507419.
8. Vulliamy T, Beswick R, Kirwan M, Marrone A, Digweed M, Walne A, Dokal I. Mutations in the telomerase component NHP2 cause the premature ageing syndrome dyskeratosis congenita. Proc Natl Acad Sci USA 2008, 105:8073-8078. 10.1073/pnas.0800042105, 2430361, 18523010.
9. Savage SA, Giri N, Baerlocher GM, Orr N, Lansdorp PM, Alter BP. TINF2, a component of the shelterin telomere protection complex, is mutated in dyskeratosis congenita. Am J Hum Genet 2008, 82:501-509. 10.1016/j.ajhg.2007.10.004, 2427222, 18252230.
10. Zhong F, Savage SA, Shkreli M, Giri N, Jessop L, Myers T, Chen R, Alter BP, Artandi SE. Disruption of telomerase trafficking by TCAB1 mutation causes dyskeratosis congenita. Genes and Development 2011, 25.
11. Dokal I. Dyskeratosis congenita in all its forms. Br J Haematol 2000, 110:768-779. 10.1046/j.1365-2141.2000.02109.x, 11054058.
12. Vulliamy TJ, Marrone A, Knight SW, Walne A, Mason PJ, Dokal I. Mutations in dyskeratosis congenita: their impact on telomere length and the diversity of clinical presentation. Blood 2006, 107:2680-2685. 10.1182/blood-2005-07-2622, 16332973.
13. Joint Statement of the American Thoracic Society and the European Respiratory Society, Idiopathic pulmonary fibrosis: diagnosis and treatment. Am J Respir Crit Care Med 2000, 161:646-664.
14. Diaz de LA, Cronkhite JT, Katzenstein AL, Godwin JD, Raghu G, Glazer CS, Rosenblatt RL, Girod CE, Garrity ER, Xing C, Garcia CK. Telomere lengths, pulmonary fibrosis and telomerase (TERT) mutations. PLoS One 2010, 5:e10680. 10.1371/journal.pone.0010680, 2873288, 20502709.
15. Tsakiri KD, Cronkhite JT, Kuan PJ, Xing C, Raghu G, Weissler JC, Rosenblatt RL, Shay JW, Garcia CK. Adult-onset pulmonary fibrosis caused by mutations in telomerase. Proc Natl Acad Sci USA 2007, 104:7552-7557. 10.1073/pnas.0701009104, 1855917, 17460043.
16. Mason DP, Brizzio ME, Alster JM, McNeill AM, Murthy SC, Budev MM, Mehta AC, Minai OA, Pettersson GB, Blackstone EH. Lung transplantation for idiopathic pulmonary fibrosis. Ann Thorac Surg 2007, 84:1121-1128. 10.1016/j.athoracsur.2007.04.096, 17888957.
17. Faro A, Mallory GB, Visner GA, Elidemir O, Mogayzel PJ, Danziger-Isakov L, Michaels M, Sweet S, Michelson P, Paranjape S, Conrad C, Waltz DA. American Society of Transplantation executive summary on pediatric lung transplantation. Am J Transplant 2007, 7:285-292. 10.1111/j.1600-6143.2006.01612.x, 17109726.
18. Pechet TV, de le MM, Mendeloff EN, Sweet SC, Shapiro SD, Huddleston CB. Lung transplantation in children following treatment for malignancy. J Heart Lung Transplant 2003, 22:154-160. 10.1016/S1053-2498(02)00671-X, 12581763.
19. Armanios M, Chen JL, Chang YP, Brodsky RA, Hawkins A, Griffin CA, Eshleman JR, Cohen AR, Chakravarti A, Hamosh A, Greider CW. Haploinsufficiency of telomerase reverse transcriptase leads to anticipation in autosomal dominant dyskeratosis congenita. Proc Natl Acad Sci USA 2005, 102:15960-15964. 10.1073/pnas.0508124102, 1276104, 16247010.
20. Marrone A, Sokhal P, Walne A, Beswick R, Kirwan M, Killick S, Williams M, Marsh J, Vulliamy T, Dokal I. Functional characterization of novel telomerase RNA (TERC) mutations in patients with diverse clinical and pathological presentations. Haematologica 2007, 92:1013-1020. 10.3324/haematol.11407, 2892775, 17640862.
21. Basel-Vanagaite L, Dokal I, Tamary H, Avigdor A, Garty BZ, Volkov A, Vulliamy T. Expanding the clinical phenotype of autosomal dominant dyskeratosis congenita caused by TERT mutations. Haematologica 2008, 93:943-944. 10.3324/haematol.12317, 18460650.
22. Calado RT, Regal JA, Kleiner DE, Schrump DS, Peterson NR, Pons V, Chanock SJ, Lansdorp PM, Young NS. A spectrum of severe familial liver disorders associate with telomerase mutations. PLoS One 2009, 4:e7926. 10.1371/journal.pone.0007926, 2775683, 19936245.
23. Amarasinghe K, Dalley C, Dokal I, Laurie A, Gupta V, Marsh J. Late death after unrelated-BMT for dyskeratosis congenita following conditioning with alemtuzumab, fludarabine and melphalan. Bone Marrow Transplant 2007, 40:913-914. 10.1038/sj.bmt.1705839, 17724438.
24. Armanios MY, Chen JJ, Cogan JD, Alder JK, Ingersoll RG, Markin C, Lawson WE, Xie M, Vulto I, Phillips JA, Lansdorp PM, Greider CW, Loyd JE. Telomerase mutations in families with idiopathic pulmonary fibrosis. N Engl J Med 2007, 356:1317-1326. 10.1056/NEJMoa066157, 17392301.
25. Dietz AC, Orchard PJ, Baker KS, Giller RH, Savage SA, Alter BP, Tolar J. Disease-specific hematopoietic cell transplantation: nonmyeloablative conditioning regimen for dyskeratosis congenita. Bone Marrow Transplant 2010,
26. Vuong LG, Hemmati PG, Neuburger S, Terwey TH, Vulliamy T, Dokal I, le Coutre P, Dörken B, Arnold R. Reduced-intensity conditioning using fludarabine and antithymocyte globulin alone allows stable engraftment in a patient with dyskeratosis congenita. Acta Haematol 2010, 124:200-203. 10.1159/000318721, 21042011.
27. Elizur A, Faro A, Huddleston CB, Gandhi SK, White D, Kuklinski CA, Sweet SC. Lung transplantation in infants and toddlers from 1990 to 2004 at St. Louis Children's Hospital. Am J Transplant 2009, 9:719-726. 10.1111/j.1600-6143.2009.02552.x, 19344463.
28. Aurora P, Edwards LB, Kucheryavaya AY, Christie JD, Dobbels F, Kirk R, Rahmel AO, Stehlik J, Hertz MI. The Registry of the International Society for Heart and Lung Transplantation: thirteenth official pediatric lung and heart-lung transplantation report--2010. J Heart Lung Transplant 2010, 29:1129-1141. 10.1016/j.healun.2010.08.008, 20870167.
29. Koszewski BJ, Hubbard TF. Congenital anemia in hereditary ectodermal dysplasia. AMA Arch Derm 1956, 74:159-166.
30. Bryan HG, Nixon RK. Dyskeratosis congenita and familial pancytopenia. JAMA 1965, 192:203-208.
31. Inoue S, Mekanik G, Mahallati M, Zuelzer WW. Dyskeratosis congenita with pancytopenia. Another constitutional anemia. Am J Dis Child 1973, 126:389-396.
32. Robledo AA, Gomez F, Tojo SR, Larripa P. Dyskeratosis congenita Zinsser-Cole-Engmann form with abnormal karyotype. Dermatologica 1974, 148:98-103. 10.1159/000251605, 4837655.
33. Paul SR, Perez-Atayde A, Williams DA. Interstitial pulmonary disease associated with dyskeratosis congenita. Am J Pediatr Hematol Oncol 1992, 14:89-92. 10.1097/00043426-199221000-00015, 1550271.
34. Verra F, Kouzan S, Saiag P, Bignon J, de CH. Bronchoalveolar disease in dyskeratosis congenita. Eur Respir J 1992, 5:497-499.
35. Imokawa S, Sato A, Toyoshima M, Yoshitomi A, Tamura R, Suda T, Suganuma H, Yagi T, Iwata M, Hayakawa H, Chida K. Dyskeratosis congenita showing usual interstitial pneumonia. Intern Med 1994, 33:226-230. 10.2169/internalmedicine.33.226, 8069018.
36. Yel L, Tezcan I, Sanal O, Ersoy F, Berkel AI. Dyskeratosis congenita: unusual onset with isolated neutropenia at an early age. Acta Paediatr Jpn 1996, 38:288-290.
37. Kilic S, Kose H, Ozturk H. Pulmonary involvement in a patient with dyskeratosis congenita. Pediatr Int 2003, 45:740-742. 10.1111/j.1442-200X.2003.01820.x, 14651554.
38. Devriendt K, Matthijs G, Legius E, Schollen E, Blockmans D, van Geet C, Degreef H, Cassiman JJ, Fryns JP. Skewed X-chromosome inactivation in female carriers of dyskeratosis congenita. Am J Hum Genet 1997, 60:581-587. 1712491, 9042917.
39. Vanbiervliet P, Blockmans D, Bobbaers H. Dyskeratosis congenita and associated interstitial lung disease: a case report. Acta Clin Belg 1998, 53:198-202.
40. Nakamura Y, Iwata M, Ida M, Oda S, Takeuchi E, Asada K, Nakano H, Horiguchi T, Ooi S, Sato A. [A case of dyskeratosis congenita with acute interstitial pneumonia]. Nihon Kyobu Shikkan Gakkai Zasshi 1997, 35:985-990.
41. Safa WF, Lestringant GG, Frossard PM. X-linked dyskeratosis congenita: restrictive pulmonary disease and a novel mutation. Thorax 2001, 56:891-894. 10.1136/thorax.56.11.891, 1745968, 11641517.
42. Hafsaoui C, Mahammedi H, Manzoni P, Aubin F, Dupond JL. [Dyskeratosis congenita and diffuse lung fibrosis]. Rev Med Interne 2004, 25:395-396. 10.1016/j.revmed.2003.08.009, 15110959.
43. Utz JP, Ryu JH, Myers JL, Michels VV. Usual interstitial pneumonia complicating dyskeratosis congenita. Mayo Clin Proc 2005, 80:817-821. 10.4065/80.6.817, 15945534.
44. Castori M, Ceccarini C, Castiglia D, Ruggeri S, Dallapiccola B, Zambruno G. Delayed diagnosis of dyskeratosis congenita in a 40-year-old woman with multiple head and neck squamous cell carcinomas. Br J Dermatol 2007, 156:406-408. 10.1111/j.1365-2133.2006.07661.x, 17223904.
45. Reimann C, Kloeckener-Gruissem B, Niemeyer CM, Vanscheidt W. Late manifestation of dyskeratosis congenita presenting as chronic dermal ulcer in a 37-year-old man. J Eur Acad Dermatol Venereol 2008, 22:897-898. 10.1111/j.1468-3083.2007.02530.x, 18070020.
46. Walne AJ, Vulliamy T, Beswick R, Kirwan M, Dokal I. TINF2 mutations result in very short telomeres: analysis of a large cohort of patients with dyskeratosis congenita and related bone marrow failure syndromes. Blood 2008, 112:3594-3600. 10.1182/blood-2008-05-153445, 2572788, 18669893.
47. Boueiz A, Abougergi MS, Noujeim C, Assaf EB, Jamaleddine G. Fatal bilateral pneumothoraces complicating dyskeratosis congenita: a case report. J Med Case Reports 2009, 3:6622. 10.1186/1752-1947-3-6622, 2726487, 19830116.
48. Knudson M, Kulkarni S, Ballas ZK, Bessler M, Goldman F. Association of immune abnormalities with telomere shortening in autosomal-dominant dyskeratosis congenita. Blood 2005, 105:682-688. 10.1182/blood-2004-04-1673, 15238429.
49. Ling NS, Fenske NA, Julius RL, Espinoza CG, Drake LA. Dyskeratosis congenita in a girl simulating chronic graft-vs-host disease. Arch Dermatol 1985, 121:1424-1428. 10.1001/archderm.121.11.1424, 3901930.
50. Langston AA, Sanders JE, Deeg HJ, Crawford SW, Anasetti C, Sullivan KM, Flowers ME, Storb R. Allogeneic marrow transplantation for aplastic anaemia associated with dyskeratosis congenita. Br J Haematol 1996, 92:758-765. 10.1046/j.1365-2141.1996.424984.x, 8616050.
51. Conter V, Johnson FL, Paolucci P, Ruggiero M, Janco RL. Bone Marrow Transplantation for Aplastic Anemia Associated with Dyskeratosis Congenita. Am J Pediatr Hematol Oncol 1988, 10:99-102.
52. Yabe M, Yabe H, Hattori K, Morimoto T, Hinohara T, Takakura I, Shimizu T, Shimamura K, Tang X, Kato S. Fatal interstitial pulmonary disease in a patient with dyskeratosis congenita after allogeneic bone marrow transplantation. Bone Marrow Transplant 1997, 19:389-392. 10.1038/sj.bmt.1700674, 9051251.
53. Rocha V, Devergie A, Socie G, Ribaud P, Esperou H, Parquet N, Gluckman E. Unusual complications after bone marrow transplantation for dyskeratosis congenita. Br J Haematol 1998, 103:243-248. 10.1046/j.1365-2141.1998.00949.x, 9792316.
54. Davidovich E, Eimerl D, Aker M, Shapira J, Peretz B. Dyskeratosis congenita: dental management of a medically complex child. Pediatr Dent 2005, 27:244-248.
55. Amarasinghe K, Dalley C, Dokal I, Laurie A, Gupta V, Marsh J. Late death after unrelated-BMT for dyskeratosis congenita following conditioning with alemtuzumab, fludarabine and melphalan. Bone Marrow Transplant 2007, 40:913-914. 10.1038/sj.bmt.1705839, 17724438.